Evidence map›Paper›PMID 36013246›Full record

ArticleJournal of personalized medicine2022

Real-World Evaluation of a Population Germline Genetic Screening Initiative for Family Medicine Patients.

Megan Leigh Hutchcraft, Shulin Zhang, Nan Lin, Ginny Lee Gottschalk, James W Keck, Elizabeth A Belcher, Catherine Sears, Chi Wang, Kun Liu, Lauren E Dietz and 5 more

Open access · goldAbstract read
In one paragraph

Article in Journal of personalized medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Megan Leigh HutchcraftDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Kentucky Markey Cancer Center, Lexington, KY 40536, USA.ORCID 0000-0002-8611-6324
Shulin ZhangDepartment of Pathology and Laboratory Medicine, University of Kentucky Chandler Medical Center, Lexington, KY 40536, USA.
Nan LinDepartment of Pharmacy Practice and Science, University of Kentucky College of Pharmacy, Lexington, KY 40506, USA.
Ginny Lee GottschalkDepartment of Family and Community Medicine, University of Kentucky Chandler Medical Center, Lexington, KY 40536, USA.
James W KeckDepartment of Family and Community Medicine, University of Kentucky Chandler Medical Center, Lexington, KY 40536, USA.ORCID 0000-0001-7193-065X
Elizabeth A BelcherDepartment of Clinical Research, University of Kentucky Markey Cancer Center, Lexington, KY 40536, USA.
Catherine SearsDepartment of Pathology and Laboratory Medicine, University of Kentucky Chandler Medical Center, Lexington, KY 40536, USA.
Chi WangShared Resource Facility, University of Kentucky Markey Cancer Center, Lexington, KY 40536, USA.
Kun LiuDr. Bing Zhang Department of Statistics, University of Kentucky, Lexington, KY 40536, USA.
Lauren E DietzDepartment of Pharmacy Practice and Science, University of Kentucky College of Pharmacy, Lexington, KY 40506, USA.
Justine C PickarskiUniversity of Kentucky Markey Cancer Center, Lexington, KY 40536, USA.
Sainan WeiDepartment of Pathology and Laboratory Medicine, University of Kentucky Chandler Medical Center, Lexington, KY 40536, USA.
Roberto CardarelliDepartment of Family and Community Medicine, University of Kentucky Chandler Medical Center, Lexington, KY 40536, USA.
Robert S DiPaolaUniversity of Kentucky Markey Cancer Center, Lexington, KY 40536, USA.
Jill M KolesarDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Kentucky Markey Cancer Center, Lexington, KY 40536, USA.ORCID 0000-0003-1802-6439
University of Kentucky · USAlbert B. Chandler Hospital · US

Funding

University of Kentucky Markey Cancer Center Support Grant ECIA SupplementP30CA177558 · NCI · UNIVERSITY OF KENTUCKY · PI Jennifer F Rogers · 2013 to 2026
$38.3M
NCI NIH HHS P30 CA177558NCI NIH HHS P30CA177558
6 · The paper itself

Abstract

Hereditary factors contribute to disease development and drug pharmacokinetics. The risk of hereditary disease development can be attenuated or eliminated by early screening or risk reducing interventions. The purpose of this study was to assess the clinical utility of germline medical exome sequencing in patients recruited from a family medicine clinic and compare the mutation frequency of hereditary predisposition genes to established general population frequencies. At the University of Kentucky, 205 family medicine patients underwent sequencing in a Clinical Laboratory Improvement Amendments of 1988-compliant laboratory to identify clinically actionable genomic findings. The study identified pathogenic or likely pathogenic genetic variants-classified according to the American College of Medical Genetics and Genomics variant classification guidelines-and actionable pharmacogenomic variants, as defined by the Clinical Pharmacogenetics Implementation Consortium. Test results for patients with pharmacogenomic variants and pathogenic or likely pathogenic variants were returned to the participant and enrolling physician. Hereditary disease predisposition gene mutations in

Indexed as

family medicinegenetic screeningpharmacogenomicsreal-world

Identifiers

PMID36013246
PMCPMC9410316
OpenAlexW4293777577

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.